Eli Zavialov PhD

Dr. Eli Zavialov is currently a Senior Director and Head of the Biopharm CMC Regulatory Affairs group at GSK. In this role, Eli is leading a department responsible for developing and implementing global CMC regulatory strategies and submissions for a diverse portfolio of biologics. Prior to joining GSK, Eli served as a Scientific Director, Regulatory CMC Dossier Development and Operations at J&J. Eli joined Johnson & Johnson in 2011, where he made significant contributions to the preparation and delivery of technical CMC sections to support global clinical trial and marketing applications across a diverse portfolio of biologics, vaccines, and small molecules. In addition, Eli served as a single point of contact for GRA CMC senior leadership on strategic dossier content needs and requirements and was accountable for continuous excellence with regard to dossier submissions. Prior to joining Johnson & Johnson, Eli worked in Chemical Development and Technical Operations at Merck and Schering-Plough in various positions of increasing responsibility overseeing the development and scaleup of manufacturing processes for NMEs. Eli is in active member of several cross-industry professional groups and societies including ACS and ISPE.